Global CRDMO leader, WuXi STA, is making a significant stride in pharmaceutical manufacturing with the launch of a high potency, fully automated sterile injectable manufacturing line at its site in Wuxi City. This state-of-the-art line represents a considerable enhancement in WuXi STA’s manufacturing capabilities and capacity to meet the demands of the high potency pharmaceuticals market.
The key feature of the new manufacturing line is its focus on maintaining a sterile and safe environment. With fully enclosed isolation systems and automated filling machines, the line minimizes human intervention, thus significantly reducing the risk of cross-contamination. Additionally, the integration of an independent air conditioning system and a bag-in bag-out (BIBO) exhaust air purification system highlights WuXi STA’s commitment to safeguarding the health of its operators and the environment.
As part of its ambitious growth strategy, WuXi STA plans to introduce two more injectable manufacturing lines at the same site by 2024. Dr. Minzhang Chen, Co-CEO of WuXi AppTec and CEO of WuXi STA, shares his excitement about this milestone, reiterating WuXi STA’s commitment to strengthen its CRDMO platform capabilities and to accelerate the development and availability of new therapeutics for patients around the globe.
